ISPOR OUTLINES NEW STRATEGIC VISION AT 18th ANNUAL EUROPEAN CONGRESS

Published Nov 10, 2015

ISPOR UPDATES STRATEGY IN ITS 20th ANNIVERSARY YEAR 

Milan, Italy—November 10, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) outlined the organization’s updated strategic vision this morning during its member meeting at the 18th Annual European Congress in Milan, Italy. ISPOR President Daniel C. Malone, RPh, PhD and CEO Nancy Berg presented ISPOR’s new organizational strategy, an update of ISPOR’s Vision 2020, the current strategic plan. ISPOR’s new Mission Statement to promote health economics and outcomes research excellence to improve decision making for health globally is supported by five strategic pillars:
  1. Scientific and Research Excellence
  2. Member Engagement
  3. Education and Training
  4. Communication and Collaboration
  5. Organizational Values
“We are very excited to introduce ISPOR’s new strategic vision to our members,” noted Berg. “Our updated strategy was developed by ISPOR’s Strategic Planning Working Group and approved by the ISPOR Board with input from many members.” In his comments, Malone emphasized the Society’s commitment to strengthen the integrity, advancement, and understanding of health economics and outcomes research globally. Additional information on ISPOR’s updated strategic vision may be found at http://www.ispor.org/mission.asp. ISPOR’s 18th Annual European Congress may be followed on social media using the hashtag #ISPORMilan.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×